Early Feasibility Study Begins for Ancora Heart's AccuCinch Transcatheter Heart Failure Therapy
June 3, 2019—Ancora Heart, Inc. announced the first patient was enrolled in a United States early feasibility study evaluating the company's AccuCinch ventricular repair system as a treatment for patients with reduced ejection fraction systolic heart failure.
According to the company, the AccuCinch system is designed to repair the left ventricle of the heart directly, thereby addressing the fundamental issue in the progression of systolic heart failure.
Ancora Heart's transcatheter AccuCinch therapy is designed to complement and enhance the existing care that cardiologists provide to further manage symptoms and slow, or stop, the progression of heart failure. For some patients, AccuCinch may have the potential to reverse the enlargement of the left ventricle. For patients where heart failure has progressed beyond the ability for medications and pacemakers to manage symptoms, nonsurgical percutaneous device therapy with AccuCinch may provide an effective treatment option, stated the company.
The study will enroll up to 15 patients from heart centers across the country. The first patient was enrolled at UPMC Pinnacle Harrisburg in Harrisburg, Pennsylvania, by interventional cardiologist Hemal Gada, MD, Medical Director of the Structural Heart Program, and Mubashir Mumtaz, MD, Chief of Cardiothoracic Surgery and Surgical Director of Structural Heart.
In Ancora Heart's announcement, Dr. Gada stated, “We are pleased to participate in this study because it is the first in the world to evaluate a transcatheter therapy for heart failure that seeks to restore quality of life and longevity by directly improving left ventricular heart function.”
The company noted that this is the second United States early feasibility study evaluating the safety of the AccuCinch system. In May 2018, Ancora Heart announced that the FDA allowed the expansion of patient enrollment in the initial study evaluating the AccuCinch system in patients with heart failure and functional mitral regurgitation.
These two AccuCinch studies are enrolling patients simultaneously and are being conducted under the same investigational device exemption approved by the FDA.
advertisement
Featured Video
Conquer the Calcium.
Deliver the Stent.
Sponsored by Cardiovascular Systems Inc.
Related Articles
Top 5 Articles From April 2019
TAVI: Which Valve for Which Patient?
A review of the technical challenges and optimal valve choices in different clinical and anatomic scenarios.
By Noman Ali, PhD; and Daniel J. Blackman, MD
Permanent Pacemaker Implantation After TAVR
Reviewing the current landscape of permanent pacemaker implantation post-TAVR and a look at the road ahead.
By Rahul Sharma, MD; and Rahul P. Sharma, MD
Bioprosthetic Valve Fracture During ViV TAVR
A step-by-step practical guide for performing BVF to facilitate ViV TAVR.
By Ahmed Almomani, MD; and Adnan K. Chhatriwalla, MD
Roundtable Discussion: TAVR in Low-Risk Patients
Experts discuss the significance of recent data and the potential impact on their practice.
With Kentaro Hayashida, MD, PhD, FESC, FACC, FJCS; Robert Ostfeld, MD, MSc, FACC; Bernard Prendergast, BMedSci, BM BS, MRCP, DM, FRCP, FESC; Michael J. Reardon, MD; and Steven J. Yakubov, MD, FACC, FSCAI
Simultaneous Measurement of Differential Pressures With a Dual Lumen Catheter
Using a dual lumen catheter to accurately measure pressures between two sites across a valve or stenosis.
By Christian Bradaric, MD
Top 5 from EVToday's Current Issue
What’s New in Y-90?
Technical and procedural innovations in Y-90 radioembolization including existing and investigational next-generation technologies.
By Robert Abraham, MD, FRCPC, FSIR; Robert Lewandowski, MD, FSIR; Ripal T. Gandhi, MD, FSIR, FSVM; and David M. Liu, MD, FRCPC, FSIR
Transradial Access for Hepatic Oncologic Interventions
Considerations for choosing the right access equipment.
By Darren Klass, MBChB, MD, MRCS, FCRC, FRCPC; Anastasia Hadjivassiliou, MBBS, FRCR, FRCPC; and John Chung, MD, FRCPC
Is It Time to End the Therapeutic Nihilism Toward Treating VTE in Cancer Patients?
Cases highlighting the potential for early benefit and improved quality of life and function associated with the use of FlowTriever and ClotTriever Systems in patients with cancer and VTE.
With Sirish A. Kishore, MD; and William C. Dillon, MD, FACC
Contemporary Management of Pancreatic Cancer
An update on state-of-the-art minimally invasive therapies, including recent advances in surgery, radiation therapy, ablative options, and endovascular therapies.
By Ripal T. Gandhi, MD, FSIR, FSVM; Horacio Asbun, MD; Michael Chuong, MD; Filipe Kunzler, MD; and Govindarajan Narayanan, MD
Top Tips in Interventional Oncology
Clinical and technical insights into treating hepatocellular carcinoma, cholangiocarcinoma, renal cell carcinoma, lung cancer, bone cancer, and in the palliative care setting.
